Aesther Healthcare Acquisition Corp.
AEHA
NASDAQ Global Market9.96
USD
+0.22
- -
CIK
0001869974
ISIN
US00809L1061
CUSIP
00809L106
Return %
Stock
S&P500
1Y
-0.99
26.53
3Y
-0.09
76.60
5Y
-0.09
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Surendra K. Ajjarapu
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 515 Madison Avenue New York City NY United States of America 10022
- IPO Date
- Nov 5, 2021
- CIK
- 0001869974
- Similar Companies
- Business
- Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) is a blank check company, or special purpose acquisition company (SPAC), formed to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting innovative companies in the healthcare sector, including pharmaceuticals, biotechnology, medical devices, healthcare services, telehealth, and related technologies; it offers no current operational products or services beyond its SPAC structure, which holds cash raised from its initial public offering primarily in trust for distribution upon a successful de-SPAC transaction or liquidation. Founded in 2021 and headquartered at 515 Madison Avenue, Suite 8078, New York, New York, the company focuses on early- and growth-stage healthcare businesses that improve delivery and outcomes through transformative technologies, with operations centered in the United States and potential global deal sourcing. In February 2023, Aesther completed a reverse merger with Ocean Biomedical, Inc., pursuant to which Ocean became a wholly owned subsidiary, Aesther rebranded its common stock and warrants under new Nasdaq symbols OCEA and OCEAW, and issued approximately 23.4 million shares of Class A common stock to Ocean shareholders along with up to an additional 19 million shares contingent on post-merger stock performance; the transaction included backstop agreements totaling up to $80 million from investors such as Meteora and Vellar Opportunity Fund to support funding, a $75 million common stock purchase commitment from White Lion Capital, and aimed to provide around $105 million in gross proceeds assuming minimal redemptions to fuel Ocean's pipeline in oncology, fibrosis, and infectious diseases backed by $123.9 million in prior grants. Prior to this, Aesther terminated a potential deal with United Gear in July 2022 and extended its combination deadline multiple times, including to December 2022, while maintaining sufficient trust funds to cover redemptions and potential excise taxes. As of late 2025, the entity operates as potentially delisted or inactive under its original ticker, with legacy trust assets and post-merger status tied to Ocean Biomedical's clinical-stage biopharmaceutical advancements.